Cambridge, MA-based Warp Drive Bio is launching a new cancer drug platform which the biotech claims will open up new, previously undruggable targets to developers. The work is built on their insights into a "novel composite surface" that can be used to target cancer with new therapies. And their first target--RAS--encompasses both the challenges as well as the potential of what they're trying to do. Release